DiaMedica Therapeutics
DMAC
89 hedge funds and large institutions have $87.8M invested in DiaMedica Therapeutics in 2026 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 32 increasing their positions, 20 reducing their positions, and 19 closing their positions.
950% more call options, than puts
Call options by funds: $21K | Put options by funds: $2K
60% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 20
11% more capital invested
Capital invested by funds: $79.2M → $87.8M (+$8.64M)
0.68% more ownership
Funds ownership: 22.46% → 23.15% (+0.68%)
10% less funds holding
Funds holding: 99 → 89 (-10)
42% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 19
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CLG
Cooperman Leon G
|
+$8.79M |
| 2 |
BlackRock
New York
|
+$2.43M |
| 3 |
Squarepoint
New York
|
+$893K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$698K |
| 5 |
Goldman Sachs
New York
|
+$668K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
-$3.08M |
| 2 |
SEI Investments
Oaks,
Pennsylvania
|
-$754K |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$619K |
| 4 |
Millennium Management
New York
|
-$555K |
| 5 |
KCM
Kalehua Capital Management
Dallas,
Texas
|
-$423K |
DMAC Hedge Fund Activity: Q2 2026 in Review
89 of the 8,317 institutional investors tracked by Wall St. Rank reported a position in DiaMedica Therapeutics (DMAC) for Q2 2026, worth a combined $87.8M — up 11% from $79.2M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of DMAC and 11 opened new positions — a net loss of 8 holders — while 20 trimmed existing stakes and 32 added.
The largest buyer was Cooperman Leon G, adding an estimated $8.79M. The largest seller was First Manhattan, exiting entirely with an estimated $3.08M sold.
- 89 institutional investors held DiaMedica Therapeutics (DMAC) as of Q2 2026, down from 99 in Q1 2026.
- Funds reported $87.8M of DiaMedica Therapeutics stock for Q2 2026, up 11% quarter-over-quarter.
- 11 funds opened new DiaMedica Therapeutics positions in Q2 2026 and 19 closed out, a net change of -8 holders.
- The largest DiaMedica Therapeutics buyer in Q2 2026 was Cooperman Leon G, an estimated $8.79M added.
- The largest DiaMedica Therapeutics seller in Q2 2026 was First Manhattan, an estimated $3.08M sold.
Based on aggregated 13F filings for Q2 2026.